Sangamo Therapeutics, Inc (SGMOQ)

Name: Sangamo Therapeutics, Inc (SGMOQ) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name SANGAMO THERAPEUTICS, INC · CIK 0001001233 · OTC · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Sangamo Therapeutics, Inc reported revenue of $39.55M. Revenue fell 31.6% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $34.56M.

Key ratios (year ended 2025-12-31)

-306.5%

Operating margin

-310.8%

Net margin

-31.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-21

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$34.56M	$39.55M	$57.80M	$176.23M	$111.30M	$110.70M	$118.19M	$102.43M	$84.45M	$36.57M	$19.39M
R&D Expense	$113.23M	$112.67M	$111.52M	$234.06M	$249.90M	$230.82M	$180.65M	$145.92M	$114.87M	$65.73M	$65.62M
Operating Income	-$123.56M	-$121.24M	-$103.97M	-$274.00M	-$201.28M	-$183.34M	-$129.55M	-$105.18M	-$77.15M	-$56.36M	-$72.56M
Depreciation & Amortization	$3.66M	$3.96M	$5.11M	$15.06M	$12.11M	$9.44M	$5.68M	$3.93M	$2.36M	$1.50M	$997.0K
EBITDA	-$119.90M	-$117.28M	-$98.86M	-$258.94M	-$189.17M	-$173.90M	-$123.87M	-$101.25M	-$74.79M	-$54.86M	-$71.56M
Net Income	-$123.33M	-$122.93M	-$97.94M	-$257.83M	-$192.28M	-$178.29M	-$121.00M	-$95.19M	-$68.33M	-$54.57M	-$71.66M
EPS (Diluted)	n/a	-$0.44	-$0.49	-$1.48	-$1.25	-$1.23	-$0.90	-$0.85	n/a	n/a	n/a
Total Assets	$59.97M	$59.74M	$101.64M	$165.32M	$562.51M	$721.92M	$938.55M	$637.52M	$590.39M	$286.74M	$157.89M
Total Liabilities	$78.92M	$74.01M	$78.86M	$82.43M	$267.55M	$346.58M	$441.18M	$204.78M	$223.14M	$98.84M	$21.70M
Shareholders' Equity	-$18.95M	-$14.27M	$22.77M	$82.89M	$294.96M	$375.34M	$498.23M	$432.55M	$366.52M	$187.90M	$136.19M
Cash & Equivalents	$27.59M	$20.95M	$41.92M	$45.20M	$100.44M	$178.87M	$131.33M	$80.43M	$140.42M	$49.83M	$22.06M
Operating Cash Flow	-$90.34M	-$97.21M	-$67.14M	-$224.84M	-$223.63M	-$233.25M	$169.88M	-$144.40M	$36.55M	$11.18M	-$65.88M
Capital Expenditures	$115.0K	$102.0K	$267.0K	$21.16M	$20.17M	$23.28M	$14.71M	$20.68M	$43.06M	$3.75M	$732.0K
Free Cash Flow	-$90.46M	-$97.31M	-$67.41M	-$246.00M	-$243.80M	-$256.53M	$155.16M	-$165.08M	-$6.51M	$7.43M	-$66.61M
Shares Outstanding	n/a	350.69M	212.84M	178.13M	166.79M	145.92M	142.06M	115.97M	102.19M	85.60M	70.87M
Weighted Average Diluted Shares	n/a	280.19M	201.70M	174.44M	154.34M	144.57M	134.45M	112.11M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.44	-$0.49	-$1.48	-$1.25	-$1.23	-$0.90	-$0.85	n/a	n/a	n/a